Praluent (Alirocumab for Solution for Subcutaneous Injection): Uses, Dosage, Side Effects, Interactions, Warning
Praluent (alirocumab) dosing, indications, interactions, adverse effects, and more
- Indicated as an adjunct to diet, alone or in combination with other lipid-lowering therapies (eg, statins, ezetimibe), for treatment of adults with primary hyperlipidemia to reduce low-density lipoprotein cholesterol (LDL-C)
- Indicated to reduce the risk of MI, stroke, and unstable angina requiring hospitalization in adults with established cardiovascular disease
- Recommended starting dose: 75 mg SC q2Weeks
- Measure CLC-C levels within 4-8 week of initiating; if inadequate response, may increase to 150 mg SC q2Weeks; reassess LDL-C within 4-8 weeks
- Not to exceed 150 mg SC q2Weeks
- Recommended starting dose: 300 mg SC q4Weeks (ie, two 150-mg injections consecutively at 2 different injection sites)
- Measure LDL-C just prior to the next scheduled dose; if inadequate response, may adjust dose to 150 mg q2Weeks, starting the new dose on the next scheduled dosing date; reassess LDL-C within 4-8 weeks
- 150 mg SC q2Weeks
- May be administered without regard to timing of apheresis
- Mild or moderate: No dose adjustment required
- Severe: Not studied
- Mild or moderate: No dose adjustment required
- Severe: Not studied
